You are here: Industry Insights > Cetuximab

News List

First-in-Human Clinical Data Shows SonoTran® is Safe and Well-Tolerated PharmaSources
January 23, 2023
OxSonics Therapeutics, announces that first-in-human clinical data demonstrated that SonoTran® is safe and well-tolerated, with consistent Particle activation observed and mapped using OxSonics’ proprietary “see-as-you-treat” technology.
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab PharmaSources
January 19, 2023
SOTIO Biotech announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa (previously known as SOT101), an IL-15 superagonist, and cetuximab in patients with colorectal cancer.
Jacobio Receives IND Approval for Combination Therapy of KRAS G12C and Cetuximab Injection in China prnasia
December 06, 2021
Jacobio Pharma (1167.HK) has received the Investigational New Drug (the "IND") approval of the combination therapy of KRAS G12C inhibitor JAB-21822 and Cetuximab injection from the Center for Drug Evaluation of China (the "CDE") on Dec 3, 2021.
FDA Approves New Dosing Regimen for Cetuximab americanpharmaceuticalreview
April 12, 2021
On April 6, 2021, the Food and Drug Administration approved a new dosage regimen of 500 mg/m2 as a 120-minute intravenous infusion every two weeks (Q2W) for cetuximab (Erbitux, ImClone LLC) for patients with K-Ras wild-type, EGFR-expressing colorectal ...
Pierre Fabre gets EC nod for Braftovi plus cetuximab to treat BRAFV600E-mutant mCRC pharmaceutical-business-review
June 08, 2020
Pierre Fabre has secured approval from the European Commission (EC) for Braftovi (encorafenib) plus cetuximab (Erbitux) to treat adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) who have received prior systemic therapy.
Junshi Biosciences, Merck Partner on SCCHN Combo Therapy contractpharma
June 02, 2020
To study anti-PD-1 mAb toripalimab (TUOYI) in combination with Cetuximab (Erbitux) in metastatic squamous cell carcinomas of the head and neck in China.
FDA Approves Encorafenib, Cetuximab Combination for Metastatic Colorectal Cancer americanpharmaceuticalreview
April 10, 2020
The U.S. Food and Drug Administration (FDA) approved encorafenib (BRAFTOVI, Array BioPharma) in combination with cetuximab for the treatment of adult patients ...